[NICE Technology appraisal guidance] Lenalidomide plus dexamethasone for previously untreated multiple myeloma

NICE | June 2019 | Lenalidomide plus dexamethasone for previously untreated multiple myeloma Technology appraisal guidance [TA587]

NICE has published evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

Full details from NICE 

Of interest: [Technology Appraisal Guidance] Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s